Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition

Cell Cycle

Volumn 7, Issue 7, 2008, Pages 940-949

  Poruchynsky, Marianne S ^a   Sackett, Dan L ^a   Robey, Robert W ^a   Ward, Yvona ^b   Annunziata, Christina ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Microtubule stabilization; Multiple myeloma; Neurotoxicity; Polymerization; Proteasome inhibitors; Tubulin; tubulin acetylation

Indexed keywords

ALPHA TUBULIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; EPOTHILONE A; EPOXOMYCIN; LACTACYSTIN; MICROTUBULE ASSOCIATED PROTEIN; PACLITAXEL; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; VIMENTIN;

AGGRESOME; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROTUBULE ASSEMBLY; MULTIPLE MYELOMA; NERVE CELL; NEUROBLASTOMA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN STABILITY; TISSUE CULTURE; UPREGULATION;

EID: 42449130530     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.7.5625     Document Type: Article

References (58)

1. Goldberg AL, Akopian TN, Kisselev AF, Lee DH. Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors. Mol Biol Rep 1997; 24:69-75.
2. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426:895-9.
3. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65:801-47.
4. Schmidt M, Hanna J, Elsasser S, Finley D. Proteasome-associated proteins: regulation of a proteolytic machine. Biol Chem 2005; 386:725-37.
5. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82:373-428.
6. Ciechanover A, Schwartz AL. Ubiquitin-mediated degradation of cellular proteins in health and disease. Hepatology 2002; 35:3-6.
7. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17:1807-19.
8. Ardley HC, Scott GB, Rose SA, Tan NG, Markham AF, Robinson PA. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell 2003; 14:4541-56.
9. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143:1883-98.
10. Ehrhardt AG, Sluder G. Spindle pole fragmentation due to proteasome inhibition. J Cell Physiol 2005; 204:808-18.
11. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102:8567-72.
12. Orlowski RZ, Zeger ZL. Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opinion Investig. Drug 2006; 15:117-30.
13. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57:33-47.
14. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46:189-213.
15. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomycin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999; 96:10403-8.
16. Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 2001; 78:899-908.
17. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-25.
18. Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry 2004; 43:13944-54.
19. Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol 2001; 62:1469-80.
20. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-34.
21. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115:727-38.
22. An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 2007; 6:61-9.
23. 2-M phase arrest and apoptosis. Mol Cancer Ther 2002; 1:841-9.
24. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-22.
25. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006; 98:1142-57.
26. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-6.
27. Kim KB and Crews CM. Natural product and synthetic proteasome inhibitors. In Proteasome Inhibitors in Cancer Therapy, ed J Adams. Totowa, NJ, Humana Press 2004; 47-63.
28. Imajoh Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995; 217:1070-7.
29. Balan KV, Wang Y, Chen SW, Chen JC, Zheng LF, Yang L, Liu ZL, Pantazis P, Wyche JH, Han Z. Proteasome-independent downregulation of estrogen receptor-alpha (ERalpha) in breast cancer cells treated with 4,4′-dihydroxy-trans-stilbene. Biochem Pharmacol 2006; 72:573-81. Epub 2006 Jul 5. Erratum in: Biochem Pharmacol 2007; 73:163-4.
30. Sun X, Gulyas M, Hjerpe A, Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 2006; 232:161-9.
31. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NFkappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NFkappa B. EMBO J 1994; 13:5433-41.
32. Crawford Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, Irvine AE. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006; 66:6379-86.
33. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J Jr. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006; 28:439-46.
34. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005; 24:344-54.
35. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66:3773-81.
36. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-20.
37. Luduena RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998; 178:207-75.
38. Cross D, Dominguez J, Maccioni RB, Avila J. MAP-1 and MAP-2 binding sites at the C-terminus of beta-tubulin. Studies with synthetic tubulin peptides. Biochemistry 1991; 30:4362-6.
39. Maccioni RB, Vera JC, Dominguez J, Avila J. A discrete repeated sequence defines a tubulin binding domain on microtubule-associated protein tau. Arch Biochem Biophys 1989; 275:568-79.
40. Downing KH, Nogales E. Tubulin and microtubule structure. Curr Opin Cell Biol 1998; 10:16-22.
41. Kamath K, Wilson L, Cabral F, Jordan MA. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005; 280:12902-7.
42. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997; 36:3554-62.
43. Khan IA, Luduena RF. Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Invest New Drugs 2003; 21:3-13.
44. Italiano JE Jr, Bergmeier W, Tiwari S, Falet H, Hartwig JH, Hoffmeister KM, Andre P, Wagner DD, Shivdasani RA. Mechanisms and implications of platelet discoid shape. Blood 2003; 101:4789-96.
45. Schwer HD, Lecine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol 2001; 11:579-86.
46. Hartwig J, Italiano J Jr. The birth of the platelet. J Thromb Haemost 2003; 1:1580-6.
47. Lecine P, Italiano JE Jr, Kim SW, Villeval JL, Shivdasani RA. Hematopoietic-specific beta 1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2. Blood 2000; 96:1366-73.
48. Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002; 3:388-96.
49. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10:524-30.
50. Grune T, Jung T, Merker K, Davies KJ. Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease. Int J Biochem Cell Biol 2004; 36:2519-30.
51. Webb JL, Ravikumar B, Rubinsztein DC. Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases. Int J Biochem Cell Biol 2004; 36:2541-50.
52. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108:3441-9. Epub 2006.
53. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115:727-38.
54. Lowe J, Mayer J, Landon M, Layfield R. Ubiquitin and the molecular pathology of neurodegenerative diseases. Adv Exp Med Biol 2001; 487:169-86.
55. Friedenberg WR, Graham D, Greipp P, Blood E, Winston RD. The treatment of multiple myeloma with docetaxel (an ECOG study). Leuk Res 2003; 27:751-4.
56. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol 1998; 21:553-6.
57. Gazitt Y, Shaughnessy P, Rothenberg ML. A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients. Oncol Rep 2006; 16:877-84.
58. Whitehurst, AW, Bodemann, BO, Cardenas, J, Ferguson, D, Girard, L, Peyton, M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature Apr 2007; 446:815-9.